Newly published research shows Avandia poses roughly the same heart-attack risk as competing drug Actos, contradicting earlier studies suggesting Avandia was more dangerous.
The new study, published this week in the journal Circulation: Cardiovascular Quality and Outcomes, may have arrived at a different conclusion in part because its subjects may have been younger and healthier than in previous studies, says study author Debra (more…)
